Obesity-associated respiratory complications range from simple dyspnea on exertion to life-threatening obesity hypoventilation syndrome (OHS). The latter, defined by PaCO2 >45 torr in individuals with body mass index (BMI) >30kg/m2 and no alternative cause of hypercapnia, is associated with severe cardiac complications and increased mortality. While inability of the lungs to expand against abdominal and thoracic adipose tissue is thought to drive this ventilatory compromise, clinical studies have also identified respiratory muscle weakness in obese patients. Moreover, large adipocyte inclusions are seen in diaphragms of subjects with OHS but not in obese/normocapnic or lean individuals. These findings suggest the diaphragm itself may be compromised with obesity; however, impacts of over-nutrition on structure and function of this muscle are not well defined. In mice subjected to a long-term diet-induced obesity (DIO) time course, we observed hypercapnia after 6 months high fat diet (HFD) feeding. This temporally corresponded with impaired diaphragm muscle function?assessed in vivo by ultrasonography and ex vivo by measurement of contractile force. Adipose tissue expansion and collagen deposition within the diaphragm temporally corresponded with hypercapnia and quantitatively correlated with ex vivo contractile deficits. Lineage tracing showed all intra-diaphragmatic adipocytes and many collagen-producing cells to arise from fibro-adipogenic progenitors (FAPs), a skeletal muscle mesenchymal stem cell population. FAP number, proliferation, and collagen deposition increased with obesity. We hypothesize that FAP-mediated, fibro-adipogenic remodeling of the diaphragm impairs ventilatory function in obesity.
In Aim 1, we will test whether obesity per se impairs ventilation and diaphragm function by analyzing weight-matched genetically obese and DIO mice. Ex vivo, we will measure contractile function and passive stiffness of large muscle isolates and individual myofibers to determine whether biomechanical defects occur at the tissue or cellular level. Finally, we will determine quantitative correlations of intra-diaphragmatic adipocyte number and polymerized collagen with these physiologic parameters.
In Aim 2, we specifically test the hypothesis that FAPs mediate diaphragm fibro-adipogenic remodeling and dysfunction in obesity. We will analyze FAP response to obesity with global gene expression profiling and ex vivo proliferation, adipogenesis and collagen deposition quantification. We will then determine whether (diphtheria toxin-mediated) FAP ablation prevents diaphragm fibro-adipogenic changes and dysfunction in a DIO model.
In Aim 3, we will analyze tissue samples and FAPs isolated from human autopsy samples to determine whether similar changes occur in obese humans and associate with clinical OHS diagnosis. The work will define a cellular mechanism of OHS; and completion of the project will provide training in muscle biomechanics, RNA-Seq and human sample analysis.
Obesity hypoventilation syndrome is a high-risk ventilatory failure impacting at least 1/160 Americans and conferring 2-fold increased risk of cardiovascular events and mortality. While OHS is generally thought driven by restricted lung expansion in the setting of increased visceral and thoracic adipose tissue, our preliminary data show mice with an OHS-like phenotype to display anatomic remodeling and functional compromise of the diaphragm itself. This proposal aims to fully characterize these structure-function relationships and determine the cellular mechanism of diaphragmatic dysfunction in mice, while establishing a clear link between diaphragm remodeling and OHS in humans.
